Safetyand tolerability of active immunotherapy CAD106 in two phase ii studies in alzheimer's patients

Authors
Category Primary study
JournalAlzheimer's and Dementia
Year 2011
This article has no abstract
Epistemonikos ID: 9b1d730999bb75b9308ec34381d7bdac211e38b9
First added on: Feb 04, 2025